Key clinical point:
Major finding: Less than 1% of infants with severe hemophilia A developed inhibitors after 75 exposure days.
Study details: An observational study involving 1,038 previously untreated patients with severe hemophilia A, of which 899 (87%) were followed until 75 exposure days.
Disclosures: Dr. van den Berg reported having no relevant financial disclosures.
van den Berg HM et al. EAHAD 2019, Abstract OR05.